3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
132
Pancreatic Neoplasms
36
Esophageal Neoplasms
19
Biliary Tract Neoplasms
18
Colorectal Neoplasms
17
Esophageal Squamous Cell Carcinoma
12
Neoplasm Metastasis
10
Cholangiocarcinoma
7
Carcinoma, Non-Small-Cell Lung
7
Gastrointestinal Neoplasms
6
Nasopharyngeal Carcinoma
5
Colonic Neoplasms
5
Adenocarcinoma
5
Neoplasms
4
Head and Neck Neoplasms
4
Advanced Pancreatic Cancer
4
Advanced Gastric Cancer
4
Recurrence
3
Rectal Neoplasms
3
Gastric Adenocarcinoma
3
Advanced Solid Tumors
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
NSCLC
2
Locally Advanced Pancreatic Cancer
2
Locally Advanced Gastric Cancer
2
Gastric Cancer Peritoneal Metastases
2
Gallbladder Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Interventions
Gemcitabine
5
130-nm albumin-bound paclitaxel
3
nimotuzumab
2
Oxaliplatin
2
Leucovorin
2
Irinotecan
2
Fluorouracil
2
Albumin-Bound Paclitaxel
2
surufatinib
1
napabucasin
1
irinotecan sucrosofate
1
ensituximab
1
Taxes
1
S 1 (combination)
1
Radiofrequency Ablation
1
Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pancreatic cancer, adult
×
S 1 (combination)
×
Clear all
NCT06584227
2025-12-08
ACPC
Jinling Hospital, China
Phase 2
Recruiting
45 enrolled